INTRODUCTION:
Many studies have proved the role, efficacy and safety profile of intralesional bleomycin in the management of hypertrophic scars and keloids. 1 Liposomes, by virtue of their lipid bilayer, have potential to enhance the delivery of drug to the desired area. Drugs encapsulated in liposomes are expected to be transported without rapid degradation and minimum side effects to the recipients. 2 Hence, the permeability of the drug to the cell is increased many folds. Combining this property of liposomes with the intralesional injection of Bleomycin, we conducted a study to assess whether the effect of bleomycin can be augmented by liposomal delivery system.
METHODS:
The study was conducted over a period of 24 months among patients presenting with hypertrophic scars and keloids in a tertiary care teaching hospital. The patients were divided into two study groups namely Group A and Group B. Group A patients received standard intralesional bleomycin therapy and Group B patients received liposomal based bleomycin for their scars. The injections were scheduled at monthly intervals for three consecutive months. They were followed over a period of 12 months. Scar assessment was done by calculating its volume and Vancouver Scar Scale (VSS). Symptoms of pain and pruritis were recorded using the Patient and Observer Scar Assessment Scale (POSAS). Other features and complications like skin atrophy, erythema, ulceration, necrosis, hypopigmentation or hyperpigmentation were also recorded.
RESULTS:
Fifty patients were enrolled in the study. We observed that there was decrease in scar volume by 90.17% in Group B patients whereas the Group A patients had volume reduction by 80.11%. This difference was highly significant on statistical analysis. Similarly, statistically significant difference was noticed in POSAS for pain and pruritis. No systemic side effects were noticed.
CONCLUSION:
Liposomal based bleomycin was more effective than plain bleomycin in the treatment of hypertrophic scars and keloids. Considering significantly better results, liposomal based bleomycin can be a potential option in the management of hypertrophic scars and keloids.
